Lipocine Stock Performance
| LPCN Stock | USD 3.14 0.03 0.96% |
Lipocine has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.39, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Lipocine's returns are expected to increase less than the market. However, during the bear market, the loss of holding Lipocine is expected to be smaller as well. Lipocine right now secures a risk of 4.18%. Please verify Lipocine value at risk, as well as the relationship between the skewness and day median price , to decide if Lipocine will be following its current price movements.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Lipocine are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental indicators, Lipocine may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
Last Split Factor 1:17 | Last Split Date 2023-05-12 |
1 | Lipocine Updates Corporate Presentation for Stakeholders - TipRanks | 05/12/2025 |
2 | Lipocines LPCN 1148 Highlighted in the June 2025 Edition of Hepatology LPCN Stock News | 05/22/2025 |
3 | Lipocine Receives Buy Rating from HC Wainwright Co. LPCN Stock News | 05/29/2025 |
4 | Acquisition by Higuchi John W. of 1764 shares of Lipocine at 3.2 subject to Rule 16b-3 | 06/04/2025 |
5 | Lipocine Announces Filing of New Drug Submission for TLANDO in | 06/09/2025 |
6 | Lipocine to Host Virtual RD Investor Event to Discuss LPCN 1154 as a Treatment for Postpartum Depression on July 9, 2025 | 06/23/2025 |
7 | Lipocine says first patient dosed in Phase 3 clinical trial of LPCN 1154 LPCN | 06/26/2025 |
8 | Lipocine begins dosing in Phase III postpartum depression trial of LPCN 1154 | 06/27/2025 |
9 | Lipocine Updates Corporate Presentation for Investors - TipRanks | 07/02/2025 |
| Begin Period Cash Flow | 4.8 M |
Lipocine Relative Risk vs. Return Landscape
If you would invest 306.00 in Lipocine on April 9, 2025 and sell it today you would earn a total of 12.00 from holding Lipocine or generate 3.92% return on investment over 90 days. Lipocine is currently generating 0.1465% in daily expected returns and assumes 4.1755% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Lipocine, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lipocine Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lipocine's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lipocine, and traders can use it to determine the average amount a Lipocine's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0351
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | LPCN | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.18 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.15 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average Lipocine is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lipocine by adding it to a well-diversified portfolio.
Lipocine Fundamentals Growth
Lipocine Stock prices reflect investors' perceptions of the future prospects and financial health of Lipocine, and Lipocine fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lipocine Stock performance.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (1.46) % | ||||
| Operating Margin | (22.27) % | ||||
| Current Valuation | (3.08 M) | ||||
| Shares Outstanding | 5.35 M | ||||
| Price To Earning | 15.80 X | ||||
| Price To Book | 0.87 X | ||||
| Price To Sales | 4.53 X | ||||
| Revenue | 11.2 M | ||||
| Gross Profit | 3.67 M | ||||
| EBITDA | (1.11 M) | ||||
| Net Income | 8.35 K | ||||
| Cash And Equivalents | 37.4 M | ||||
| Cash Per Share | 0.42 X | ||||
| Total Debt | 1.51 M | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 3.59 X | ||||
| Cash Flow From Operations | (1.22 M) | ||||
| Earnings Per Share | (1.01) X | ||||
| Total Asset | 22.51 M | ||||
| Retained Earnings | (199.77 M) | ||||
| Current Asset | 29.41 M | ||||
| Current Liabilities | 1.57 M | ||||
About Lipocine Performance
By examining Lipocine's fundamental ratios, stakeholders can obtain critical insights into Lipocine's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Lipocine is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression LPCN 2101 for women with epilepsy, which has completed pre-clinical study and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birthThings to note about Lipocine performance evaluation
Checking the ongoing alerts about Lipocine for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lipocine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lipocine had very high historical volatility over the last 90 days | |
| Lipocine has high likelihood to experience some financial distress in the next 2 years | |
| Lipocine currently holds about 37.4 M in cash with (1.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.42. | |
| Lipocine has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Lipocine Updates Corporate Presentation for Investors - TipRanks |
- Analyzing Lipocine's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lipocine's stock is overvalued or undervalued compared to its peers.
- Examining Lipocine's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lipocine's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lipocine's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lipocine's stock. These opinions can provide insight into Lipocine's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.01) | Revenue Per Share 0.687 | Quarterly Revenue Growth (0.99) | Return On Assets (0.18) | Return On Equity |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.